Isentress(raltegravir,
or MK-0518) First
Integrase Inhibitor, Raltegravir (Isentress), Receives FDA Approval for
Treatment-experienced HIV Patients -
10/16/07
Raltegravir
(Isentress) Demonstrates Sustained Viral Suppression through 48 Weeks in Treatment-experienced
Patients - 9/26/07
FDA
Committee Recommends Approval of First Integrase Inhibitor, Raltegravir (Isentress,
MK-0518) - 9/07/07
Raltegravir
Demonstrates
Rapid and Durable Anti-HIV Activity as Part of Combination Therapy in Treatment-naive
Patients - 9/07/07
Experimental
Integrase Inhibitor Raltegravir Achieves HIV Viral Load Reductions Comparable
to Sustiva and Shows a More Favorable Lipid and Tolerability Profile in Treatment-naïve
Patients - 7/27/07
FDA
to Hold Raltegravir (Isentress) Hearing on September 5, 2007 in Silver
Springs - 7/13/07
FDA
Grants Priority Review for Merck's Investigational HIV Integrase Inhibitor
Raltegravir (Isentress)
- 6/29/07
Integrase
Inhibitor Raltegravir Demonstrates Potent Activity Against HIV at 16-24
Weeks - 3/06/07
HIV
Integrase Inhibitor MK-0518 Monotherapy Demonstrates Potent Anti-HIV Activity
in 10-day Study 12/08/06
Pharmacokinetics
and Dosing of MK-0518 in Healthy Volunteers
10/10/06 New
Data on MK-0518 Drug Interactions
10/10/06 Differential
Effect of MK-0518 and Efavirenz on Serum Lipids Levels
10/10/06
MK-0518, Experimental Integrase Inhibitor from
Merck, Shows Significant Potency in HIV Patients with Triple-class Resistant Virus
9/29/06
Two
Expanded Access Programs Now Available to Provide Free Access to the Experimental
HIV Medications MK-0518 and TMC125 9/20/06
Free
Access Opens to MK-0518, Experimental HIV Integrase Inhibitor from Merck
9/12/06
MK-0518
Integrase Inhibitor Is Active Against HIV through Week 24 - 8/22/06
Merck
Announces Interim Results from Phase II Study of MK-0518, an Investigational
Oral HIV Integrase Inhibitor
2/10/06
|
|
|
|
